ADMdx

Turning images into insights

Menu
  • Home
  • About us
    • About ADMdx
    • Management team
    • Collaborations
  • Clinical trials
    • Capabilities
    • Subject inclusion
    • Enrichment and stratification
    • Detecting treatment effect
    • Data insight for planning & discovery
    • Our technology
  • Diagnostics
    • Overview
    • Dementia diagnostics
    • About dementias
    • About imaging
  • Publications
  • Contact
  • News

ADMdx to present insights to relationships between tau, glucose metabolism, and atrophy using PET and MRI imaging

December 10, 2019 By Dawn Matthews

ADMdx will present findings regarding relationships between tau, glucose metabolism, brain atrophy, and patient characteristics at the ADPD conference in April 2020. These analyses used a unique data set acquired through the Phase II study of the drug rasagiline in Alzheimer’s disease patients in collaboration with Dr. Jeffrey Cummings of the Cleveland Clinic. The data provides new insights regarding these biomarkers in Alzheimer’s disease.

Filed Under: News

Copyright © 2021 ADM Diagnostics, Inc.